|
【摘要】 目的：探讨联合检测血清中的αL岩藻糖苷酶(AFU)、甲胎蛋白(AFP)在预测肝癌术后复发的价值。方法：分别检测3组AFU、AFP，AFU 检测均采用比色速率法测定，设定AFU>40U/L、GPDA>41U/L为阳性界定值。AFP检测采用微粒子酶免法，设定AFP>13.6μg/L为阳性界定值。结果：AFU、AFP水平A组与B组及正常对照组比较差异有统计学意义(P<0.001);AFU、AFP水平B组较正常对照组高，但差异无统计学意义(P>0.05);AFU、AFP水平A组肝癌复发前、后比较差异有统计学意义(P<0.001);敏感性、准确性AFU+AFP与AFU、AFP比较差异有统计学意义(P<0.001)，AFU与AFP比较差异无统计学意义(P>0.05);特异性AFU+AFP、AFU、AFP两两比较差异无统计学意义(P>0.05)。结论：联合检测血清中AFU、AFP水平可显著提高肝癌术后复发的诊断率，可作为预测肝癌术后复发的检测指标。 【关键词】 肝癌;复发;αL岩藻糖苷酶;甲胎蛋白;诊断 幸福检验网www.xf366.com感谢作者对论文的分享！ Diagnosis value of combined detection of serum tumor markers in predicting recurrence in patients with liver cancer FAN Congjin (The 171 Hospical of People's Liberation Army,Jiujiang 332000, China) [ABSTRACT] Objective: To explore diagnosis value of the combined detection of serum AFU, AFP in predicting postoperative recurrence of hepatocellular carcinoma. Methods: The serum AFU, AFP levels were detected in three groups, AFU detection rate was used by colorimetric determination, respectively, set the AFU>40 U / L, GPDA>41 U / L defined as positive values. AFP was detected by microparticle enzyme immunoassay, set AFP> 13. 6μg / L defined as positive values. Results: AFU, AFP levels of group A, group B and normal control group were significantly different (P<0.001); AFU, AFP levels of group B were higher than that of the normal control group, but no significant difference (P>0.05). AFU, AFP levels of group A before and after HCC recurrence were significant difference (P<0.001). Sensitivity, accuracy of AFU + AFP and AFU, AFP were significantly different when compared (P<0.001); AFU and AFP were no significant difference (P>0.05); specificity of AFU + AFP, AFU, AFP were no significant differences (P>0.05). Conclusion: The combined detection of serum AFU, AFP levels could significantly improve the diagnostic rate of liver cancer recurrence, may be as a predictor of postoperative recurrence of liver cancer detection indicators. [KEY WORDS] Hepatocellular carcinoma; Recurrence; AFU; AFP; Diagnosis 原发性肝癌为临床一种常见病，是全球五大恶性肿瘤之一，调查显示其发病率还在逐年升高。目前，外科手术治疗仍然是可能治愈肝癌的唯一方法。然而，手术治疗后复发率和转移率较高，导致术后生存期较短、长期生存率较低[1]。研究表明，原发性肝癌患者行根治性切除术治疗后5年复发率达61.5%[2]。肝癌的发病机制是一个复杂的多因素、多步骤的过程。所以目前仍无一种特异性检测指标可在临床上预测或诊断肝癌的转移、复发[3，4]。我们发现通过联合检测血清中的αL岩藻糖苷酶(AFU)和甲胎蛋白(AFP)2种肿瘤标志物可早期发现肝癌的复发与转移，从而可进行早期治疗，延长患者生存期。现将结果报告如下。 1 资料与方法 1.1 一般资料 选取病例均为2007年1月～2008年12月在我院肝胆外科行肝癌根治术的肝癌术后患者，随访1年后分别选取临床资料完整的肝癌术后复发患者(A组)与肝癌术后未复发患者(B组)各30例。A组中男性19例，女性11例;年龄29～71岁，平均(51.5±5.6)岁。B组中男性18例，女性12例;年龄30～73岁，平均(52.5±5.4)岁。同时将在我院行体检的健康者30例设为正常对照组，其中男性20例，女性10例;年龄30～72岁，平均(52.3±5.3)岁。3组性别组成、年龄分布等一般资料比较差异无统计学意义(P>0.05)，具有可比性。 |